Amoy Diagnostics300685.SZValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 19, 2026, Amoy Diagnostics (300685.SZ) trades at a P/E of 21.10x, P/B of 3.78x, P/S of 6.40x, and a dividend yield of 2.43%.
Longitudinal percentile comparison: P/E sits at the 5th percentile over the trailing 10Y window (vs. 14th percentile over 3Y); P/B sits at the 5th percentile over the trailing 10Y window (vs. 16th percentile over 3Y); P/S sits at the 4th percentile over the trailing 10Y window (vs. 11th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 24th percentile within its industry and the 27th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 2.76%, ranking at the 96th percentile over the trailing 20Y window.
Cross-checking P/E against P/B, the two percentiles sit within 0.6 points of each other — a consistent signal from both angles. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Of the 2.76% total shareholder yield, 2.43% is paid out as dividends and roughly 0.33% is implied to come from buybacks — both channels are meaningfully in play. Amoy Diagnostics operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHE: 300685 · SZSE: 300685 · 300685
Want the full picture on whether Amoy Diagnostics (300685.SZ) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 21.10 | ||||||
| P/B (MRQ) | 3.78 | ||||||
| P/S (TTM) | 6.40 | ||||||
| Dividend Yield | 2.43% | ||||||
| Buyback + Div Yield | 2.76% |